Logo image of EGRX

EAGLE PHARMACEUTICALS INC (EGRX) Stock Fundamental Analysis

USA - NASDAQ:EGRX - US2697961082 - Common Stock

2.14 USD
-1.42 (-39.89%)
Last: 10/2/2024, 8:06:00 PM
2.28 USD
+0.14 (+6.54%)
After Hours: 10/2/2024, 8:06:00 PM
Fundamental Rating

4

Taking everything into account, EGRX scores 4 out of 10 in our fundamental rating. EGRX was compared to 540 industry peers in the Biotechnology industry. There are concerns on the financial health of EGRX while its profitability can be described as average. EGRX has a valuation in line with the averages, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

6

1. Profitability

1.1 Basic Checks

In the past year EGRX was profitable.
In the past year EGRX has reported a negative cash flow from operations.
EGRX had positive earnings in 4 of the past 5 years.
Each year in the past 5 years EGRX had a positive operating cash flow.
EGRX Yearly Net Income VS EBIT VS OCF VS FCFEGRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 20M 40M 60M 80M 100M

1.2 Ratios

The Return On Assets of EGRX (2.99%) is better than 94.01% of its industry peers.
EGRX has a Return On Equity of 4.80%. This is amongst the best in the industry. EGRX outperforms 94.54% of its industry peers.
Looking at the Return On Invested Capital, with a value of 10.53%, EGRX belongs to the top of the industry, outperforming 95.77% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for EGRX is below the industry average of 15.95%.
Industry RankSector Rank
ROA 2.99%
ROE 4.8%
ROIC 10.53%
ROA(3y)3.37%
ROA(5y)5.82%
ROE(3y)5.61%
ROE(5y)8.93%
ROIC(3y)13.59%
ROIC(5y)13.5%
EGRX Yearly ROA, ROE, ROICEGRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 0 10 20 30 40 50

1.3 Margins

The Profit Margin of EGRX (4.70%) is better than 94.19% of its industry peers.
EGRX's Profit Margin has declined in the last couple of years.
EGRX has a Operating Margin of 16.47%. This is amongst the best in the industry. EGRX outperforms 95.77% of its industry peers.
In the last couple of years the Operating Margin of EGRX has declined.
EGRX has a Gross Margin of 69.86%. This is amongst the best in the industry. EGRX outperforms 84.33% of its industry peers.
In the last couple of years the Gross Margin of EGRX has declined.
Industry RankSector Rank
OM 16.47%
PM (TTM) 4.7%
GM 69.86%
OM growth 3Y42.71%
OM growth 5Y-1.58%
PM growth 3Y15.49%
PM growth 5Y-12.5%
GM growth 3Y0.54%
GM growth 5Y-1.58%
EGRX Yearly Profit, Operating, Gross MarginsEGRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 0 20 40 60

More info and screens

3

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so EGRX is still creating some value.
Compared to 1 year ago, EGRX has more shares outstanding
The debt/assets ratio for EGRX is higher compared to a year ago.
EGRX Yearly Shares OutstandingEGRX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 5M 10M 15M
EGRX Yearly Total Debt VS Total AssetsEGRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 100M 200M 300M 400M

2.2 Solvency

EGRX has an Altman-Z score of 1.81. This is not the best score and indicates that EGRX is in the grey zone with still only limited risk for bankruptcy at the moment.
EGRX's Altman-Z score of 1.81 is fine compared to the rest of the industry. EGRX outperforms 70.07% of its industry peers.
EGRX has a Debt/Equity ratio of 0.25. This is a healthy value indicating a solid balance between debt and equity.
EGRX has a Debt to Equity ratio of 0.25. This is in the lower half of the industry: EGRX underperforms 68.84% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.25
Debt/FCF N/A
Altman-Z 1.81
ROIC/WACC1.32
WACC7.97%
EGRX Yearly LT Debt VS Equity VS FCFEGRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 50M 100M 150M 200M

2.3 Liquidity

EGRX has a Current Ratio of 2.16. This indicates that EGRX is financially healthy and has no problem in meeting its short term obligations.
EGRX has a worse Current ratio (2.16) than 75.35% of its industry peers.
A Quick Ratio of 1.67 indicates that EGRX should not have too much problems paying its short term obligations.
With a Quick ratio value of 1.67, EGRX is not doing good in the industry: 79.58% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 2.16
Quick Ratio 1.67
EGRX Yearly Current Assets VS Current LiabilitesEGRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M

More info and screens

2

3. Growth

3.1 Past

EGRX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -33.52%.
Measured over the past years, EGRX shows a quite strong growth in Earnings Per Share. The EPS has been growing by 14.81% on average per year.
Looking at the last year, EGRX shows a decrease in Revenue. The Revenue has decreased by -5.40% in the last year.
EGRX shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 5.99% yearly.
EPS 1Y (TTM)-33.52%
EPS 3Y44.53%
EPS 5Y14.81%
EPS Q2Q%-24.36%
Revenue 1Y (TTM)-5.4%
Revenue growth 3Y17.35%
Revenue growth 5Y5.99%
Sales Q2Q%-12.76%

3.2 Future

The Earnings Per Share is expected to decrease by -11.47% on average over the next years. This is quite bad
Based on estimates for the next years, EGRX will show a small growth in Revenue. The Revenue will grow by 0.24% on average per year.
EPS Next Y-40.26%
EPS Next 2Y-34.69%
EPS Next 3Y-26.94%
EPS Next 5Y-11.47%
Revenue Next Year-19.31%
Revenue Next 2Y-18.72%
Revenue Next 3Y-11.22%
Revenue Next 5Y0.24%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
EGRX Yearly Revenue VS EstimatesEGRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 100M 200M 300M
EGRX Yearly EPS VS EstimatesEGRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2 4 6

More info and screens

6

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 0.46, the valuation of EGRX can be described as very cheap.
EGRX's Price/Earnings ratio is rather cheap when compared to the industry. EGRX is cheaper than 99.82% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 27.20. EGRX is valued rather cheaply when compared to this.
The Price/Forward Earnings ratio is 0.64, which indicates a rather cheap valuation of EGRX.
Based on the Price/Forward Earnings ratio, EGRX is valued cheaply inside the industry as 99.65% of the companies are valued more expensively.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.71, EGRX is valued rather cheaply.
Industry RankSector Rank
PE 0.46
Fwd PE 0.64
EGRX Price Earnings VS Forward Price EarningsEGRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

EGRX's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. EGRX is cheaper than 99.12% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 1.31
EGRX Per share dataEGRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

EGRX has a very decent profitability rating, which may justify a higher PE ratio.
EGRX's earnings are expected to decrease with -26.94% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)0.03
EPS Next 2Y-34.69%
EPS Next 3Y-26.94%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for EGRX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EAGLE PHARMACEUTICALS INC

NASDAQ:EGRX (10/2/2024, 8:06:00 PM)

After market: 2.28 +0.14 (+6.54%)

2.14

-1.42 (-39.89%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-06 2024-08-06/amc
Earnings (Next)11-04 2024-11-04/amc
Inst Owners66.05%
Inst Owner Change-4.72%
Ins Owners5.97%
Ins Owner Change0%
Market Cap27.80M
Analysts85.71
Price Target17.34 (710.28%)
Short Float %0.38%
Short Ratio0.22
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)13.91%
Min EPS beat(2)10.18%
Max EPS beat(2)17.65%
EPS beat(4)4
Avg EPS beat(4)19.72%
Min EPS beat(4)10.18%
Max EPS beat(4)29.93%
EPS beat(8)5
Avg EPS beat(8)-2.39%
EPS beat(12)8
Avg EPS beat(12)72.12%
EPS beat(16)11
Avg EPS beat(16)63.08%
Revenue beat(2)2
Avg Revenue beat(2)4.74%
Min Revenue beat(2)2.71%
Max Revenue beat(2)6.76%
Revenue beat(4)3
Avg Revenue beat(4)1.54%
Min Revenue beat(4)-7.39%
Max Revenue beat(4)6.76%
Revenue beat(8)3
Avg Revenue beat(8)-9.26%
Revenue beat(12)5
Avg Revenue beat(12)-7.18%
Revenue beat(16)5
Avg Revenue beat(16)-7.22%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE 0.46
Fwd PE 0.64
P/S 0.11
P/FCF N/A
P/OCF N/A
P/B 0.11
P/tB 0.28
EV/EBITDA 1.31
EPS(TTM)4.66
EY217.76%
EPS(NY)3.34
Fwd EY155.86%
FCF(TTM)-0.72
FCFYN/A
OCF(TTM)-0.72
OCFYN/A
SpS19.82
BVpS19.4
TBVpS7.67
PEG (NY)N/A
PEG (5Y)0.03
Profitability
Industry RankSector Rank
ROA 2.99%
ROE 4.8%
ROCE 13.33%
ROIC 10.53%
ROICexc 11.06%
ROICexgc 22.27%
OM 16.47%
PM (TTM) 4.7%
GM 69.86%
FCFM N/A
ROA(3y)3.37%
ROA(5y)5.82%
ROE(3y)5.61%
ROE(5y)8.93%
ROIC(3y)13.59%
ROIC(5y)13.5%
ROICexc(3y)19.91%
ROICexc(5y)21.41%
ROICexgc(3y)52.27%
ROICexgc(5y)50.12%
ROCE(3y)17.2%
ROCE(5y)17.09%
ROICexcg growth 3Y46.01%
ROICexcg growth 5Y-6.15%
ROICexc growth 3Y27.58%
ROICexc growth 5Y-11.05%
OM growth 3Y42.71%
OM growth 5Y-1.58%
PM growth 3Y15.49%
PM growth 5Y-12.5%
GM growth 3Y0.54%
GM growth 5Y-1.58%
F-Score3
Asset Turnover0.64
Health
Industry RankSector Rank
Debt/Equity 0.25
Debt/FCF N/A
Debt/EBITDA 0.98
Cap/Depr 0.34%
Cap/Sales 0.03%
Interest Coverage 10.44
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.16
Quick Ratio 1.67
Altman-Z 1.81
F-Score3
WACC7.97%
ROIC/WACC1.32
Cap/Depr(3y)10.4%
Cap/Depr(5y)10.3%
Cap/Sales(3y)0.21%
Cap/Sales(5y)0.22%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-33.52%
EPS 3Y44.53%
EPS 5Y14.81%
EPS Q2Q%-24.36%
EPS Next Y-40.26%
EPS Next 2Y-34.69%
EPS Next 3Y-26.94%
EPS Next 5Y-11.47%
Revenue 1Y (TTM)-5.4%
Revenue growth 3Y17.35%
Revenue growth 5Y5.99%
Sales Q2Q%-12.76%
Revenue Next Year-19.31%
Revenue Next 2Y-18.72%
Revenue Next 3Y-11.22%
Revenue Next 5Y0.24%
EBIT growth 1Y-45.5%
EBIT growth 3Y67.47%
EBIT growth 5Y4.32%
EBIT Next Year-37.58%
EBIT Next 3Y-26.19%
EBIT Next 5YN/A
FCF growth 1Y-121.43%
FCF growth 3Y-2.92%
FCF growth 5Y-1.22%
OCF growth 1Y-120.96%
OCF growth 3Y-3.25%
OCF growth 5Y-2.96%